Gremlin promotes vascular smooth muscle cell proliferation and migration.

[1]  T. Wagner.  Bone morphogenetic protein signaling in stem cells − one signal, many consequences , 2007, The FEBS journal.

[2]  C. Cunningham,et al.  Cross‐talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell‐specific outcomes , 2007, The FEBS journal.

[3]  D. Ribatti,et al.  Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. , 2007, Blood.

[4]  E. Canalis,et al.  Bone morphogenetic proteins and their antagonists , 2007, Reviews in Endocrine and Metabolic Disorders.

[5]  Howard Y. Chang,et al.  Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation , 2006, Proceedings of the National Academy of Sciences.

[6]  M. Runge,et al.  Thrombin and NAD(P)H Oxidase–Mediated Regulation of CD44 and BMP4-Id Pathway in VSMC, Restenosis, and Atherosclerosis , 2006, Circulation research.

[7]  A. Celeste,et al.  Bone morphogenetic proteins and growth differentiation factors as drug targets in cardiovascular and metabolic disease. , 2006, Drug discovery today.

[8]  Xu Cao,et al.  BMP Signaling and Skeletogenesis , 2006, Annals of the New York Academy of Sciences.

[9]  Dong Liu,et al.  Neuronal Chemorepellent Slit2 Inhibits Vascular Smooth Muscle Cell Migration by Suppressing Small GTPase Rac1 Activation , 2006, Circulation research.

[10]  Y. Fukuchi,et al.  Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[11]  W. L. Ruzzo,et al.  Bone morphogenetic protein 4: potential regulator of shear stress-induced graft neointimal atrophy. , 2006, Journal of vascular surgery.

[12]  J. Kim,et al.  The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein , 2006, BMC Cancer.

[13]  K. Hruska,et al.  Bone Morphogenetic Proteins in Vascular Calcification , 2005, Circulation research.

[14]  M. Kretzler,et al.  Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  K. Takeda,et al.  Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells. , 2005, International journal of molecular medicine.

[16]  Jane Y. Wu,et al.  Cutting Edge: Bone Morphogenetic Protein Antagonists Drm/Gremlin and Dan Interact with Slits and Act as Negative Regulators of Monocyte Chemotaxis12 , 2004, The Journal of Immunology.

[17]  E. Raines.  PDGF and cardiovascular disease. , 2004, Cytokine & growth factor reviews.

[18]  R. Zeller,et al.  Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis , 2004, Development.

[19]  R. Wilensky.  Angiotensin-Receptor Blockers: Revival of the Systemic Prevention of Restenosis? , 2004, Cardiovascular Drugs and Therapy.

[20]  M. Goumans,et al.  Controlling cell fate by bone morphogenetic protein receptors , 2003, Molecular and Cellular Endocrinology.

[21]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[22]  R. Weiss,et al.  BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1. , 2003, American journal of physiology. Endocrinology and metabolism.

[23]  T. Unger,et al.  Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function , 2003, Blood pressure.

[24]  P. Serruys,et al.  Effect of an anti‐PDGF‐β‐receptor‐blocking antibody on restenosis in patients undergoing elective stent placement , 2003, International journal of cardiovascular interventions.

[25]  W. Van Hul,et al.  Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. , 2002, Developmental biology.

[26]  D. Blair,et al.  Drm/Gremlin transcriptionally activates p21(Cip1) via a novel mechanism and inhibits neoplastic transformation. , 2002, Biochemical and biophysical research communications.

[27]  N. Heldin,et al.  BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). , 2001, Biochemical and biophysical research communications.

[28]  U. Vitt,et al.  Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. , 2001, Molecular endocrinology.

[29]  K. Schmidt-Ott,et al.  The multiple actions of angiotensin II in atherosclerosis , 2000, Regulatory Peptides.

[30]  S. Vukicevic,et al.  Bone morphogenetic protein‐7 (osteogenic protein‐1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro , 2000, Journal of cellular physiology.

[31]  M. Taal,et al.  IHG-2, a Mesangial Cell Gene Induced by High Glucose, Is Human gremlin , 2000, The Journal of Biological Chemistry.

[32]  B. Bardot,et al.  Biosynthesis, Post-translation Modification, and Functional Characterization of Drm/Gremlin* , 2000, The Journal of Biological Chemistry.

[33]  A. Newby,et al.  Molecular mechanisms in intimal hyperplasia , 2000, The Journal of pathology.

[34]  R. Harland,et al.  The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. , 1998, Molecular cell.

[35]  S. Schwartz.  Smooth muscle migration in atherosclerosis and restenosis. , 1997, The Journal of clinical investigation.

[36]  K. Miyazono,et al.  Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. , 1997, The Journal of clinical investigation.

[37]  David A. Mankoff,et al.  Application of Photoshop-based Image Analysis to Quantification of Hormone Receptor Expression in Breast Cancer , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[38]  S M Schwartz,et al.  The intima. Soil for atherosclerosis and restenosis. , 1995, Circulation research.

[39]  T. Ogihara,et al.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Reidy,et al.  Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. , 1991, The American journal of pathology.

[41]  G. Owens,et al.  Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells , 1988, The Journal of cell biology.